JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Kura Oncology Inc

Closed

SectorHealthcare

10.4 0.87

Overview

Share price change

24h

Current

Min

10.2

Max

10.65

Key metrics

By Trading Economics

Income

-8.7M

-66M

Sales

1.2M

15M

Profit margin

-432.509

Employees

192

EBITDA

-8M

-73M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+153.41% upside

Dividends

By Dow Jones

Next Earnings

4 lis 2025

Market Stats

By TradingEconomics

Market Cap

411M

958M

Previous open

9.53

Previous close

10.4

News Sentiment

By Acuity

50%

50%

168 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Kura Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 paź 2025, 23:32 UTC

Hot Stocks

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 paź 2025, 23:02 UTC

Earnings

AIA Group 3Q Value of New Business Grew

30 paź 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 paź 2025, 23:00 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 paź 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

30 paź 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 paź 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 paź 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 paź 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 paź 2025, 22:31 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 paź 2025, 22:29 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 paź 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q EPS 66c >BVN

30 paź 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Rev $431M >BVN

30 paź 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Net $179M >BVN

30 paź 2025, 22:16 UTC

Market Talk
Earnings

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 paź 2025, 22:14 UTC

Earnings

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 paź 2025, 22:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 paź 2025, 21:39 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 paź 2025, 21:26 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 paź 2025, 21:14 UTC

Market Talk
Earnings

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 paź 2025, 21:09 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

30 paź 2025, 21:09 UTC

Market Talk
Earnings

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 paź 2025, 21:04 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 paź 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 paź 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold Skouries on Track for 1Q of 2026

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Adj EPS 41c >EGO

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Rev $434.7M >EGO

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Net $56M >EGO

30 paź 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q EPS 27c >EGO

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

153.41% upside

12 Months Forecast

Average 26 USD  153.41%

High 40 USD

Low 11 USD

Based on 13 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

168 / 373 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat